New study tracks HS patient happiness on cosentyx
NCT ID NCT06785779
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study surveys 77 adults with moderate to severe hidradenitis suppurativa (HS) in Saudi Arabia who are starting the medication Cosentyx (secukinumab). Researchers will ask patients about their treatment satisfaction and quality of life after 24 weeks. The goal is to understand how convenient, effective, and safe patients feel the treatment is in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGRiyadh, SAU, 11525, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGJeddah, 21391, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGJeddah, 23311, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGRiyadh, 11211, Saudi Arabia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Foam could ease painful skin lumps in hidradenitis suppurativa
- Worldwide study aims to uncover hidden patterns in hidradenitis suppurativa care
- Poop pills for painful skin? fecal transplant trial targets hidradenitis
- New combo therapy aims to tame painful skin condition
- Gene-Modified cell therapy: researchers track Long-Term safety in arthritis and skin disease patients
- New hope for painful skin condition: drug trial targets chinese patients